Term
|
Definition
avoid concomitant use APAP or COX-II if possible |
|
|
Term
|
Definition
Avoid concomitant use; decrease warfarin dose by 50% pre and 1 wk post |
|
|
Term
warfarin and macrolides (especially erythromycin) |
|
Definition
interaction may be delayed; use other category, clarithromycin or azithromycin |
|
|
Term
|
Definition
use other categor; evidence strong for cipro, levo, norflxacin, enoxacin and ofloxacin |
|
|
Term
|
Definition
draw potassium levels prior to ACE initiation |
|
|
Term
GI irritation and erosion, decreased platelet adhesion |
|
Definition
|
|
Term
unknown; infection and inflammation promotes the effect of warf, may be secondatry to decrease warf degradation in the gut |
|
Definition
|
|
Term
metabolic inhibition; secondary to decreased vit K production by gut flora, may also be inflammation/ infection factor |
|
Definition
warfarin and macrolides (especially erythromycin) |
|
|
Term
metabolic inhibition; secondary to decreased vit K production by gut flora, may also be inflammation/ infection factor |
|
Definition
|
|
Term
CYP2C9 inhibitor which increases levels of S-warfarin |
|
Definition
|
|
Term
unknown; warf metabolism inhibited early effect and late effect (2-3) weeks warf metab might be induced..lack of effect |
|
Definition
|
|
Term
ACEI → ↓ aldosterone → ↓ K+ excretion |
|
Definition
|
|
Term
Additive K+ sparing effects |
|
Definition
|
|
Term
|
Definition
Draw K+ level prior to starting spironolactone |
|
|
Term
|
Definition
avoid concomitant use APAP or COX-II if possible |
|
|
Term
|
Definition
Avoid concomitant use; decrease warfarin dose by 50% pre and 1 wk post |
|
|
Term
warfarin and macrolides (especially erythromycin) |
|
Definition
interaction may be delayed; use other category, clarithromycin or azithromycin |
|
|
Term
|
Definition
use other categor; evidence strong for cipro, levo, norflxacin, enoxacin and ofloxacin |
|
|
Term
|
Definition
draw potassium levels prior to ACE initiation |
|
|
Term
GI irritation and erosion, decreased platelet adhesion |
|
Definition
|
|
Term
unknown; infection and inflammation promotes the effect of warf, may be secondatry to decrease warf degradation in the gut |
|
Definition
|
|
Term
metabolic inhibition; secondary to decreased vit K production by gut flora, may also be inflammation/ infection factor |
|
Definition
warfarin and macrolides (especially erythromycin) |
|
|
Term
metabolic inhibition; secondary to decreased vit K production by gut flora, may also be inflammation/ infection factor |
|
Definition
|
|
Term
CYP2C9 inhibitor which increases levels of S-warfarin |
|
Definition
|
|
Term
unknown; warf metabolism inhibited early effect and late effect (2-3) weeks warf metab might be induced..lack of effect |
|
Definition
|
|
Term
ACEI → ↓ aldosterone → ↓ K+ excretion |
|
Definition
|
|
Term
Additive K+ sparing effects |
|
Definition
|
|
Term
|
Definition
Draw K+ level prior to starting spironolactone |
|
|
Term
|
Definition
check baseline dig level, decrease dig dose by 50% |
|
|
Term
↓ digoxin clearance Possible additive effect on SA node? |
|
Definition
|
|
Term
|
Definition
check baseline dig level, consider dig dose reduction |
|
|
Term
Synergistic effect leading to bradycardia and heart block; decreased dig clearance |
|
Definition
|
|
Term
Theophylline + Quinolones |
|
Definition
check baseline theophylline levels, avoid enoxacin and cipro (30-40% decrease in clearance) |
|
|
Term
↓ theophylline Cl- hepatic metabolism inhibited by quinolones |
|
Definition
Theophylline + Quinolones |
|
|